42 results
424B3
ZVRA
Zevra Therapeutics Inc
10 Oct 23
Prospectus supplement
5:07pm
, the ongoing COVID-19 pandemic may materially adversely affect Acer’s ability to recruit qualified subjects for Acer’s clinical trials for Acer’s product … candidates to treat rare diseases as well as:
our ability to design and successfully execute appropriate clinical trials;
our ability to recruit
S-4/A
ZVRA
Zevra Therapeutics Inc
6 Oct 23
Registration of securities issued in business combination transactions (amended)
4:06pm
for the indications Acer is investigating. In addition, the ongoing COVID-19 pandemic may materially adversely affect Acer’s ability to recruit qualified … execute appropriate clinical trials;
our ability to recruit and enroll patients for Acer’s clinical trials;
the results of Acer’s clinical trials
S-4
ZVRA
Zevra Therapeutics Inc
28 Sep 23
Registration of securities issued in business combination transactions
9:25pm
COVID-19 pandemic may materially adversely affect Acer’s ability to recruit qualified subjects for Acer’s clinical trials for Acer’s product candidates … candidates to treat rare diseases as well as:
our ability to design and successfully execute appropriate clinical trials;
our ability to recruit
424B3
7mnj7kosq89l
10 Nov 21
Prospectus supplement
5:19pm
424B3
6353v77l8 p0lu
16 Aug 21
Prospectus supplement
12:00am
424B3
67bpvwpv93
13 May 21
Prospectus supplement
9:11pm
424B3
tyn8fyk0ugw85e9h
11 Mar 21
Prospectus supplement
9:56pm
424B4
vsmvq002mktw9dy6
8 Jan 21
Prospectus supplement with pricing info
9:38pm